Ascend is a cancer immunotherapy company developing medicines to treat primary, recurrent and metastatic cancers. Cancers are made up of many different cell types that can influence and regulate the local tumour microenvironment to promote tumour growth. Ascend’s strategy focuses on targeting these key cells and altering the host microenvironment from one that supports tumour growth to one that results in cancer eradication. The company applies a number of different technologies and approaches utilizing viral vectors, and affinity agents that can be conjugated to deliver biologicals and small molecule (immune modulators, kinase inhibitors or chemotherapeutics) payloads. We believe that applying a combination chemotherapy and immunotherapy (chemo-immunotherapy) approach has the potential to materially improve therapeutic outcomes.